#Pfizer

An NIH-sponsored study assessed boosters for adults fully vaccinated with any authorized or approved COVID-19 vaccine.

Older and immunocompromised people and those with underlying health conditions could benefit most from additional shots.

Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.

Vaccine effectiveness for children ages 5 to 11 was 91%, and serious side effects are rare.

None of the available coronavirus vaccines have been linked to increased risk of HIV acquisition or disease progression.

Many people who received any of the authorized COVID-19 vaccines are now eligible for an additional dose of their choice.

Third dose OK’d for people over 65, those at risk for severe COVID-19 and those at high risk of exposure to the coronavirus.

Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.

Who can safely receive COVID-19 vaccines?

Another vaccine, from Novavax, was 89% effective in a U.K. trial, but both were less potent against the South African coronavirus mutation.

A slow vaccine rollout and the emergence of new coronavirus mutations threaten progress in reducing new cases and death.

The technology used in COVID-19 vaccines may also be used to prevent other viral infections and to treat cancer and multiple sclerosis.

Pfizer-BioNTech’s coronavirus vaccine is 95% effective for preventing symptomatic illness.

The front-runner coronavirus vaccine appears to protect people from symptomatic disease.

Four vaccine candidates produced antibody and T-cell immune responses in the first stages of human clinical trials.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.